Three directors set to join newly merged Merck
This article was originally published in Scrip
Executive Summary
As part of the merger agreement between Merck & Co and Schering-Plough, which is expected to close in the fourth quarter, three representatives from the current Schering-Plough board are expected to remain on the board of the newly combined company upon completion of the merger: Robert Kidder, chairman and chief executive officer of 3Stone Advisors; Patricia Russo, who served as CEO of Alcatel-Lucent from 2006-08; and Dr Craig Thompson, director of the Abramson Cancer Center.